脑机接口公司何时才能有收入？马斯克的公司最新计划披露

Core Viewpoint - Neuralink aims to achieve at least $1 billion in annual revenue by 2031, with plans to implant brain-machine interface devices in 20,000 patients each year [1][2]. Group 1: Revenue and Growth Plans - Neuralink plans to operate five large clinics within the next six years and will offer three versions of brain implant devices: Telepathy for communication, Blindsight for vision restoration, and Deep for treating tremors and Parkinson's disease [1]. - The Telepathy device is expected to receive regulatory approval by 2029, with plans for 2,000 surgeries annually, generating $100 million in revenue [2]. - The Blindsight device is projected to be approved by 2030, increasing annual surgeries to 10,000 and generating over $500 million in revenue [2]. Group 2: Clinical Trials and Current Status - Currently, Neuralink has seven clinical trial patients, five of whom are severely paralyzed and are using the device to control digital and physical devices with their thoughts [1]. Group 3: Funding and Valuation - Neuralink recently announced a funding round of approximately $600 million, bringing its valuation to around $10 billion, with total funding exceeding $1.3 billion since its inception in 2016 [2]. - Notable investor Chen Tianqiao commented on the company's journey, emphasizing the need for "patient capital" in brain-machine interface investments [2].